Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: A systematic review

Annals of Family Medicine

Volumn 5, Issue 5, 2007, Pages 444-452

  Park, Ina U ^a,b   Taylor, Anne L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Antihypertensive agents; Cardiovascular diseases; Drug therapy; Ethnic groups; Evidence based medicine; Hypertension; Minority groups

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; NICARDIPINE; NIFEDIPINE; PERINDOPRIL; PLACEBO; TRANDOLAPRIL; TRICHLORMETHIAZIDE; VALSARTAN; VERAPAMIL;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ASIAN; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIURETIC THERAPY; DRUG EFFICACY; ETHNIC DIFFERENCE; ETHNICITY; EVIDENCE BASED MEDICINE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HISPANIC; HUMAN; HYPERTENSION; LOW DRUG DOSE; MINORITY GROUP; RACE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; SYSTEMATIC REVIEW;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUBJECTS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 35148835160     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.708     Document Type: Review

References (63)

1. Disparities in premature deaths from heart disease - 50 States and the District of Columbia, 2001. MMWR Morb Mortal Wkly Rep. 2004;53(6):121-125.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
3. American Heart Association. Heart disease and stroke statistics: 2006 update. 2006. http://www.americanheart.org.
4. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005;11(9):CR403-409.
5. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199-206.
6. Cochrane Library. Cochrane Review Groups(CRG), Hypertension Group. http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/HTN/frame.html. Accessed: February 23 2006.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
8. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764.
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-1762.
10. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fos-inopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597-603.
11. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366- 372.
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
13. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-365.
14. Gayet JL. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(9):1771; author reply 1771-1772.
15. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 2003;12(3):160-167.
16. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218-1226.
17. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87(9):1058-1063.
18. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751-1756.
19. Dahlof B, Hansson L, Lindholm LH, Schersten B, Ekbom T, Wester PO. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens. 1993;15(6):925-939.
20. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7):583-592.
21. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
22. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-2082.
23. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-788.
24. Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race-sex and blood pressure level. A further analysis. Hypertension Detection and Follow-up Program Cooperative Group. J Community Health. 1984;9(4):314-327.
25. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058-2068.
26. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276(23):1886-1892.
27. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270(6):713-724.
28. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
29. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-1975.
30. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9(4 Pt 1):342-360.
31. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42(3):239-246.
32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
33. Pepine CJ, Handberg-Thurmond E, Marks RG, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32(5):1228-1237.
34. Chalmers J, Neal B, MacMahon S. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee. J Hypertens Suppl. 2000;18(1):S13-19.
35. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041.
36. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
37. Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press. 2001;10(2):83-91.
38. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7(3):176-183.
39. Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10(7 Pt 1):705-713.
40. Dahlof B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32(6):989-997.
41. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004-1010.
42. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension. 1999;34(5):1129-1133.
43. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27(3):181-191.
44. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157-2172.
45. Wright JT, Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293(13):1595-1608.
46. Rodgers A, Chapman N, Woodward M, et al. Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. J Hypertens. 2004;22(3):653-659.
47. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43(6):1047-1055.
48. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens. 2006;24(11):2163-2168.
49. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens. 2003;21(7):1291-1298.
50. Cooper-DeHoff RM, Aranda JM, Jr., Gaxiola E, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151(5):1072-1079.
51. Sheikh A, Netuveli G, Kai J, Panesar SS. Comparison of reporting of ethnicity in US and European randomised controlled trials. BMJ. 2004;329(7457):87-88.
52. National Institutes of Health. NIH Policy and guidelines on the inclusion of women and minorities as subjects in clinical research. Amended, October 2001. http://grants.nih.gov.floyd.lib.umn.edu/grants/funding/women_min/ guidelines_amended_10_2001.htm. Accessed: June 30 2006.
53. Corbie-Smith G, St George DM, Moody-Ayers S, Ransohoff DF. Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. J Clin Epidemiol. 2003;56(5):416-420.
54. Tang H, Quertermous T, Rodriguez B, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet. 2005;76(2):268-275.
55. Gadegbeku CA, Lea JP, Jamerson KA. Update on disparities in the pathophysiology and management of hypertension: focus on African Americans. Med Clin North Am. 2005;89(5):921-933, 930.
56. Wright JT, Jr., Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431.
57. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525-541.
58. Matsuoka H. [Treatment of elderly hypertension based on various hypertension management guidelines-comparison between European and American guidelines and Japanese guidelines]. Nippon Rinsho. 2005;63(6):945-951.
59. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-2544.
60. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol. 2002;39(2):315-322.
61. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707-716.
62. Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185-186.
63. Taylor AL, Wright JT, Jr. Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation. 2005;112(23):3654-3660; discussion 3666.